Market Performance Summary
During the 24‑hour period ending at 02:19 AM Central Europe on Wednesday, 21 March 2026, Inspire Medical (ticker INSP) advanced 1.98 %. At the close, a single share of the company traded for approximately USD 71.34 on major exchanges. With a free float of 28.9 million shares, the market capitalization currently stands at USD 2 billion. In the preceding day, roughly USD 46 million of INSP shares were exchanged, indicating modest liquidity relative to the firm’s size.
The stock has experienced a decline of ‑7.36 % since the close of the prior month, suggesting a broader downward trend in short‑term sentiment. The 200‑day simple moving average is USD 59.68, positioning the current price well above this long‑term benchmark. Over the past year, INSP’s most favorable price was USD 147.03, recorded on 10 December 2025, while the lowest point reached USD 38.91 on 3 June 2026.
Recent Activity of Peer Companies
In the same 24‑hour window, the performance of related securities offered a mixed picture:
| Company | Ticker | % Move | Current Price (USD) | Market Cap (USD) | P/E Ratio |
|---|---|---|---|---|---|
| Rogers | ROG | +1.03 % | 136.81 | 2.4 billion | 77.09 |
| Beam Therapeutics | BEAM | +3.07 % | 24.93 | 2.4 billion | — |
| Prestige Consumer Healthcare | PBH | –0.42 % | 49.36 | 2.4 billion | 13.94 |
| Adma Biologics | ADMA | +3.65 % | 11.23 | 2.4 billion | 15.27 |
| Clover Health Investments | CLOV | –0.89 % | 4.80 | 2.4 billion | — |
The peer group’s collective performance indicates a moderate upside momentum for several growth‑oriented firms, albeit with varying valuation multiples. Notably, Rogers and Beam Therapeutics posted gains exceeding 3 %, while Prestige Consumer Healthcare and Clover Health Investments experienced slight declines.
Company Overview
Inspire Medical Systems, Inc. is a United States‑based medical‑technology enterprise that designs and manufactures implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship platform delivers electrical stimulation to the pharyngeal musculature, thereby maintaining airway patency during sleep. Founded with a vision to transform patient outcomes, Inspire has positioned itself at the intersection of neuromodulation and sleep medicine, offering solutions that can reduce dependence on continuous positive airway pressure therapy.
The firm debuted publicly on the New York Stock Exchange on 3 May 2018. Since then, Inspire has expanded its product portfolio and pursued strategic partnerships to broaden market access. Its mission emphasizes improving patients’ sleep quality and overall health through innovative, implantable technology.
